Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

In response to the news on Tuesday, the stock prices of Novo Nordisk and Hims & Hers shot up, with the latter stock price rising by nearly $10. Ro CEO Zach Reitano said, “Adding Novo Nordisk’s ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Pharmaceutical company Novo Nordisk is teaming up with direct-to-consumer telehealth company Hims & Hers to offer discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, the companies ...

Medical pioneers Hims & Hers Health HIMS and Novo Nordisk NVO are making headlines this week after announcing a partnership to expand obesity care in the telehealth space. The long-term ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...